Remove tag treatment
article thumbnail

Bluebird won't play off Vertex in deciding price for its lovo-cel gene therapy, exec says

Fierce Pharma

Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month. Two long-awaited treatments for sickle cell disease (SCD) are on the docket for FDA decisions next month. Vertex and CRISPR Therapeutics are up first with a Dec. |

FDA 224
article thumbnail

Pfizer’s First Gene Therapy Approval Sets Up a Showdown With CSL in Hemophilia B

MedCity News

The one-time treatment carries a $3.5 million price tag, the same as a CSL Behring gene therapy already available for treating the inherited bleeding disorder. The FDA has approved Beqvez, a Pfizer gene therapy developed for moderate-to-severe hemophilia B.

FDA 88
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Orchard’s MLD gene therapy becomes costliest US medicine

pharmaphorum

Orchard Therapeutics has revealed the US price of Lenmeldy, its gene therapy for rare disease MLD, placing a $4.25m price tag on the one-shot treatment

article thumbnail

NeoImmuneTech bags orphan drug tag for IL-7 acute radiation syndrome treatment

Pharmaceutical Technology

NeoImmuneTech is developing NT-17, an IL-7 treatment, to promote rapid T-cell recovery in patients with acute radiation syndrome.

article thumbnail

Revolutionizing Rare Disease Treatment: Embracing the Patient-Centric Transformation in Pharmaceutical Customer Engagement

Pharmaceutical Commerce

Navigating the complex landscape of healthcare coverage can be an intimidating task, especially for patients with rare diseases for which treatments often come with a high price tag.

article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

Still, Alzheimer’s is a nasty disease, and people are desperate for treatment even if it only provided a slim chance of partial recovery. If the drug is approved you can bet that it’s going to carry a huge price tag. Will they follow the science or will they put a price tag on hope?

article thumbnail

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Pharmaceutical Technology

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. bluebird has also proposed an outcomes-based agreement to make covering this treatment more attractive for payers.

FDA 115